Our data indicate that resmetirom can effectively ameliorate NASH by suppressing STAT3 and NF-κB signaling pathways in an RGS5-dependent manner (Figure 7D). Here, NFKB1 is linked to metabolic dysfunction-associated steatohepatitis.